SDCBP and neoplasm: Thus, this study shows that targeting SDCBP, particularly its PDZ1 domain, could be a novel alternative approach to block the BACH1 pathway and optimize anti-tumor effectiveness of FDA-approved mitochondrial inhibitor metformin as a new combinational strategy for treating patients with aggressive TNBC (Fig. 7).